Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 08:00 ET | Source: Clene Inc.

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late...
February 09, 2026 09:00 ET | Source: MS Canada

MS Canada Invites Kids, Teachers, and Book Lovers of All Ages to Join the MS Read-a-Thon Adventure this February

Toronto, ON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Starting today, the annual MS Read-a-Thon officially kicks off across Canada, challenging young readers to spend the next 30 days (February 9 – March...
January 21, 2026 12:02 ET | Source: AB Science

AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041

COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU...
January 21, 2026 12:02 ET | Source: AB Science

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...
January 20, 2026 11:15 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
January 12, 2026 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Autolus announced preliminary unaudited net product revenue from sales of AUCATZYL® (obe-cel) for the fourth quarter and full year of 2025.
October 14, 2025 08:00 ET | Source: Tr1X, Inc.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.
September 24, 2025 08:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
September 24, 2025 02:30 ET | Source: Novartis Pharma AG

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after...
August 19, 2025 10:59 ET | Source: Spherix Global Insights

Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...